Undecimal Bio Raises $18 Million in Seed Funding
Undecimal Bio, based in Cambridge, England, has announced the successful closure of an $18 million seed funding round. The company, co-founded by Shaul Ilan and Yaniv Erlich, specializes in using massive scale combinatorial chemistry paired with transformer-based AI to direct siRNA therapeutics to precise tissues in the body.
Investment Details
The seed funding round was co-led by 4BIO Capital and IQ Capital, with additional participation from Verve Ventures, Harel Tech, Entree Capital, Kerna Ventures, and Saras Capital. This financial boost is expected to drive significant advancements in Undecimal Bio's technology and operations.
Use of Funds
The newly acquired funds will be allocated towards expanding Undecimal Bio's DELiveri platform, which leverages AI to optimize the delivery of RNA medicines to specific cell types. This funding will also support the advancement of the company’s renovascular programs, focusing on diseases impacting the kidneys and blood vessels. Additionally, Undecimal Bio plans to grow its team at the Cancer Research UK Cambridge Institute to further these initiatives.
Leadership Perspective
Yaniv Erlich, Co-Founder and CEO of Undecimal Bio, has emphasized the importance of this funding in accelerating their mission to enhance targeted RNA delivery systems. This seed round marks a significant milestone for the company as it continues to develop innovative solutions in the field of siRNA therapeutics.